Mymetics Corp (MYMX)

[bow-tie]

Novel Vaccine Strategy Developed For Human Respiratory Syncytial Virus Infection
JULY 21, 2015
Remarkably, rats vaccinated with two doses of RSV VLPs [using monophosphoryl lipid A (MPLA) and alum as adjuvants to enhance immunogenicity] developed a strong neutralizing antibody response and were protected from viral infection in both the lower and upper respiratory tract. According to the authors, this is the first VLP/virosome vaccine study that resulted in a protective effect on the lower but also the upper respiratory tract.

https://lungdiseasenews.com/2015/07/21/novel-vaccine-strategy-developed-human-respiratory-syncytial-virus-infection/

So if this study was done in 2015! Using just RSV VLP/VIROSOME with the MPLA Without ALUM would work better? Since Alum causes inflammation!! Just Saying.. RSV-MPLA virosomes

? MPLA in IN-administered RSV virosomes increases serum IgG. ? MPLA in IN-administered RSV virosomes increases sIgA. ? MPLA in IN-administered RSV virosomes skews towards Th1 response. ? RSV-MPLA virosomes induce protective immunity. ? RSV-MPLA virosomes do not prime for enhanced
Taken together, these data show that mucosally administered RSV-MPLA virosomes hold promise for a safe and effective vaccine against RSV.
Covid in the Lungs?
https://www.sciencedirect.com/science/article/pii/S0264410X13002326